TABLE 1.
Demographics of included patientsb
| Parameter | Value for group |
||
|---|---|---|---|
| Not admitted | Admitted | Total | |
| Total no. (%) of patients included | 295 (100) | 113 (100) | 408 (100) |
| No. (%) of patients of age (yr) at testing (P < 0.0001) | |||
| <40# | 56 (19.0) | 3 (2.7) | 59 (14.5) |
| 40 to 59# | 82 (27.8) | 12 (10.6) | 94 (23) |
| 60 to 79 | 131 (44.4) | 61 (54.0) | 192 (47.1) |
| ≥80# | 26 (8.8) | 37 (32.7) | 63 (15.4) |
| No. (%) of patients with order location (P < 0.0001) | |||
| ED# | 166 (56.3) | 107 (94.7) | 273 (66.9) |
| Outpatient# | 71 (24.1) | 4 (3.5) | 75 (18.4) |
| Urgent care# | 58 (19.7) | 2 (1.8) | 60 (14.7) |
| No. (%) of patients with pathogen type detected (P < 0.001) | |||
| Influenza virus | 105 (35.6) | 29 (25.7) | 134 (32.8) |
| Non-influenza virus pathogen | 109 (36.9) | 29 (25.7) | 138 (33.8) |
| None# | 81 (27.5) | 55 (48.7) | 136 (33.3) |
| Mean TAT (SD) (h) | |||
| Clinical (NS) | 3.2 (4.5) | 2.3 (1.9) | 3.0 (4.0) |
| Intralaboratory (NS) | 2.0 (3.0) | 1.9 (1.7) | 2.0 (2.7) |
| No. (%) of patients with underlying lung disease (P < 0.001) | |||
| Asthma | 20 (6.8) | 2 (1.8) | 22 (5.4) |
| COPD# | 40 (13.6) | 29 (25.7)# | 69 (16.9) |
| Other | 8 (2.7) | 9 (8.0)# | 17 (4.2) |
| None | 227 (77.0) | 73 (64.6) | 300 (73.5) |
| No. (%) of patients with immunosuppression status (P = 0.003) | |||
| No | 274 (92.3) | 93 (82.3) | 367 (90) |
| Yes | 21 (7.7) | 20 (17.7) | 41 (10) |
| No. (%) of patients with clinical syndromea (P < 0.001) | |||
| Cough/URTI/bronchitis/sinusitis/pharyngitis# | 162 (54.9) | 13 (11.5) | 175 (42.9) |
| Specific viral pathogen | 53 (18.0) | 20 (17.7) | 73 (17.9) |
| Nonrespiratory syndrome | 44 (14.9) | 26 (23.0) | 70 (17.2) |
| Other respiratory syndrome# | 12 (4.1) | 14 (12.4) | 26 (6.4) |
| Pneumonia# | 9 (3.1) | 14 (12.4) | 23 (5.6) |
| COPD | 12 (4.1) | 10 (8.8) | 22 (5.4) |
| Fever/SIRS/sepsis# | 3 (1.0) | 16 (14.2) | 19 (4.7) |
a
If multiple ICD-9 codes were used for a visit, only those most directly related to respiratory virus testing were extracted.
b
All categorical data were compared with chi-squared tests. TATs were compared via a Mann-Whitney U test. For categories with significant differences, adjusted standardized residuals were calculated. # indicates an absolute value of the standardized adjusted residual of >2.58 for each row. NS, not significant; COPD, chronic obstructive pulmonary disease.